Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an <i>ATIC–ALK</i> gene fusion-Reference-Cited by-同舟云学术

Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an ATIC–ALK gene fusion

Published:2024-06-17 Issue:9 Volume:71 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Akane Yusuke¹^ORCID,Yamamoto Masaki¹,Takebayashi Akira¹^ORCID,Hamada Ryo¹,Igarashi Keita¹,Emori Makoto²,Sugita Shintaro³,Takada Kohichi⁴,Hasegawa Tadashi³,Tsugawa Takeshi¹

Affiliation:

1. Department of Pediatrics Sapporo Medical University School of Medicine Sapporo Japan

2. Department of Orthopaedic Surgery Sapporo Medical University School of Medicine Sapporo Japan

3. Department of Surgical Pathology Sapporo Medical University School of Medicine Sapporo Japan

4. Department of Medical Oncology Sapporo Medical University School of Medicine Sapporo Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.31148

Reference14 articles.

1. Consensus and controversies regarding the treatment of rhabdomyosarcoma

2. Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS)

3. Rhabdomyosarcoma in infants younger than one year old

4. Rhabdomyosarcoma in infants younger than 1 year

5. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2024-08-24